epirubicin has been researched along with Hematuria in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, K; Duan, F; Feng, DP; Fu, JX; Wang, MQ; Xin, H; Ye, HY; Yu, HK; Yuan, B; Zhang, JL; Zhang, XJ | 1 |
| Cai, S; Chen, J; Chen, P; Fang, Z; Tang, Y; Wu, S; Zhou, Y | 1 |
| Akaza, H; Hirao, Y; Hosaka, M; Ito, H; Kotake, T; Koyanagi, T; Kuroda, M; Miyanaga, N; Okajima, E; Saito, Y; Shimazaki, J | 1 |
1 review(s) available for epirubicin and Hematuria
| Article | Year |
|---|---|
Super-selective transcatheter vesical arterial chemoembolization with drug-loaded beads for muscle-invasive bladder cancer with hematuria.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Epirubicin; Hematuria; Humans; Liver Neoplasms; Muscles; Quality of Life; Retrospective Studies; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms | 2023 |
1 trial(s) available for epirubicin and Hematuria
| Article | Year |
|---|---|
[Results of clinical study with epirubicin hydrochloride injectable solution for superficial bladder cancer. IMI28 Injectable Solution Study Group for Superficial Bladder Cancer].
Topics: Administration, Intravesical; Adult; Aged; Antibiotics, Antineoplastic; Drug Administration Schedule; Epirubicin; Female; Hematuria; Humans; Male; Middle Aged; Urinary Bladder Neoplasms; Urination Disorders | 1998 |
1 other study(ies) available for epirubicin and Hematuria
| Article | Year |
|---|---|
Prostate arterial chemoembolization for treatment of refractory hematuria and urinary retention in patients with localized advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Docetaxel; Epirubicin; Hematuria; Humans; Liver Neoplasms; Male; Middle Aged; Prostate; Prostatic Neoplasms; Quality of Life; Treatment Outcome; Urinary Retention | 2023 |